Screener
EBIT at other companies
Other financials
Where this comes from
Calculated from Apogee Therapeutics, Inc.’s reported figures.
Plus components not separately reported this period.
The source filing: Apogee Therapeutics, Inc.’s 10-Q, filed May 11, 2026. Open the filing →
- Filed
- May 11, 2026, 7:20 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-215698
FAQ
- What is Apogee Therapeutics, Inc.'s EBIT?
- Apogee Therapeutics, Inc. (APGE) reported EBIT of -$82.77M in Q1 2026.
- How has Apogee Therapeutics, Inc.'s EBIT changed year-over-year?
- Apogee Therapeutics, Inc.'s EBIT decreased by 31.2% year-over-year, from -$63.1M to -$82.77M.
- What is the long-term trend for Apogee Therapeutics, Inc.'s EBIT?
- Over 2 years (2023 to 2025), Apogee Therapeutics, Inc.'s EBIT has grown at a 75.2% compound annual growth rate (CAGR), from -$93M to -$285.6M.
- What does EBIT mean?
- Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.
Ask your AI about Apogee Therapeutics, Inc.'s ebit.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude